FDA Granted Orphan Drug Designation to IMP4297+TMZ for SCLC

IMPACT Therapeutics announced that the US FDA has granted Orphan Drug Designation to their fixed-dose combination capsule of Senaparib and temozolomide (TMZ) for the treatment of adult patients with SCLC.